down arrow

Vaxcyte, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92243G1085
USD
46.07
1.37 (3.06%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

44.7947.51

52 Week

27.6694.60
Valuation
Technical
Day's Volume

CASH

1.74 M

Shareholding (Mar 2025)

FII

16.28%

Held by 164 FIIs

DII

25.09%

Held by 72 DIIs

Promoter

3.20%

How big is Vaxcyte, Inc.?

22-Jun-2025

As of Jun 18, Vaxcyte, Inc. has a market capitalization of $4.34 billion, with net sales of $0.00 million and a net profit of -$509.62 million over the latest four quarters. As of Dec 24, the company has shareholder's funds of $3.31 billion and total assets of $3.53 billion.

Market Cap: As of Jun 18, Vaxcyte, Inc. has a market capitalization of 4,339.70 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Vaxcyte, Inc. reported net sales of 0.00 million and a net profit of -509.62 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 3,305.82 million and total assets of 3,533.30 million.

Read More

What does Vaxcyte, Inc. do?

22-Jun-2025

Vaxcyte, Inc. is a mid-cap vaccine company focused on developing vaccines for infectious diseases. As of March 2025, it reported a net profit loss of $141 million and has a market cap of approximately $4.34 billion.

Overview:<BR>Vaxcyte, Inc. is a vaccine company focused on developing vaccines to prevent or treat common and deadly infectious diseases worldwide, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -141 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 4,339.70 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.52<BR>- Return on Equity: -15.93%<BR>- Price to Book: 1.36<BR><BR>Contact Details:<BR>- Address: 353 Hatch Dr, Foster City, CA 94404<BR>- Tel: 1 650 8370111<BR>- Website: https://vaxcyte.com/

Read More

Who are in the management team of Vaxcyte, Inc.?

22-Jun-2025

As of March 2022, the management team of Vaxcyte, Inc. includes Dr. Moncef Slaoui (Chairman), Mr. Grant Pickering (CEO, Co-Founder), and several directors: Ms. Halley Gilbert, Mr. Patrick Heron, Dr. Peter Hirth, Dr. Robert Hopfner, and Dr. Heath Lukatch. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Vaxcyte, Inc. includes the following individuals:<BR><BR>- Dr. Moncef Slaoui, Chairman of the Board<BR>- Mr. Grant Pickering, Chief Executive Officer, Co-Founder, Director<BR>- Ms. Halley Gilbert, Director<BR>- Mr. Patrick Heron, Director<BR>- Dr. Peter Hirth, Director<BR>- Dr. Robert Hopfner, Director<BR>- Dr. Heath Lukatch, Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Vaxcyte, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Vaxcyte, Inc. shows a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 by -72.04% compared to its 17.14% return over the past year.

As of 5 September 2025, the technical trend for Vaxcyte, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are bearish, while the weekly Bollinger Bands and KST are both mildly bearish. The overall stance is mildly bearish, reflecting a lack of strong upward momentum.<BR><BR>In terms of performance, Vaxcyte has underperformed the S&P 500 significantly over the past year, with a return of -72.04% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4,208 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.54

stock-summary
Return on Equity

-17.83%

stock-summary
Price to Book

1.37

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-167 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.52%
0%
43.52%
6 Months
32.96%
0%
32.96%
1 Year
-49.02%
0%
-49.02%
2 Years
-14.38%
0%
-14.38%
3 Years
2.58%
0%
2.58%
4 Years
138.46%
0%
138.46%
5 Years
53.57%
0%
53.57%

Vaxcyte, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Vaxcyte, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Vaxcyte, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are bearish, while the weekly Bollinger Bands and KST are both mildly bearish. The overall stance is mildly bearish, reflecting a lack of strong upward momentum. In terms of performance, Vaxcyte has underperformed the S&P 500 significantly over the past year, with a return of -72.04% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-248.55%
EBIT to Interest (avg)
-298.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.49
EV to EBIT
-4.89
EV to EBITDA
-5.02
EV to Capital Employed
2.02
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-41.44%
ROE (Latest)
-15.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 97 Schemes (55.43%)

Foreign Institutions

Held by 164 Foreign Institutions (16.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -29.45% vs -88.43% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-221.20",
          "val2": "-149.50",
          "chgp": "-47.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-166.60",
          "val2": "-128.70",
          "chgp": "-29.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.31% vs -80.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-553.70",
          "val2": "-382.90",
          "chgp": "-44.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-75.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-463.90",
          "val2": "-402.30",
          "chgp": "-15.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-221.20
-149.50
-47.96%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-166.60
-128.70
-29.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -29.45% vs -88.43% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-553.70
-382.90
-44.61%
Interest
0.00
0.00
Exceptional Items
0.00
-75.00
100.00%
Consolidate Net Profit
-463.90
-402.30
-15.31%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -15.31% vs -80.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Vaxcyte, Inc. stock-summary
stock-summary
Vaxcyte, Inc.
Pharmaceuticals & Biotechnology
Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.
Company Coordinates stock-summary
Company Details
353 Hatch Dr , FOSTER CITY CA : 94404
stock-summary
Tel: 1 650 8370111
stock-summary
https://vaxcyte.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."